

**S2 Table.** Chemotherapy regimens used according to the cancer type in male and female patients

	Total cycle planned	Female (n=493, 42.1%)	Male (n=677, 57.9%)	p-value
<b>Lung cancer</b>		168	249	0.018
Vinorelbine plus cisplatin <sup>a)</sup>	4	106 (63.1)	128 (51.4)	
Paclitaxel plus carboplatin/cisplatin <sup>b)</sup>	4	62 (36.9)	121 (48.6)	
<b>Stomach cancer</b>		147	240	0.208
Capecitabine plus oxaliplatin <sup>c)</sup>	8	32 (21.8)	66 (27.5)	
S-1 <sup>d)</sup>	8	115 (78.2)	174 (72.5)	
<b>Colon cancer</b>		178	188	0.283
5-FU/capecitabine plus oxaliplatin <sup>e)</sup>	12/8 <sup>e)</sup>	144 (80.9)	160 (85.1)	
5-FU or capecitabine <sup>f)</sup>	6/8 <sup>f)</sup>	34 (19.1)	28 (14.9)	

Values are presented as number (%). <sup>a)</sup>Vinorelbine 25 mg/m<sup>2</sup> days 1, 8+cisplatin 80 mg/m<sup>2</sup> day 1, every 3 weeks, total 4 cycles, <sup>b)</sup>Paclitaxel 175 mg/m<sup>2</sup> day 1+carboplatin AUC 5 day 1/cisplatin 60 mg/m<sup>2</sup> day 1, every 3 weeks, total 4 cycles, <sup>c)</sup>Oxaliplatin 130 mg/m<sup>2</sup> day 1+capecitabine 1,000 mg/m<sup>2</sup> P.O. bid days 1-14, every 3 weeks, total 8 cycles, <sup>d)</sup>TS-1 40 mg/m<sup>2</sup> P.O. bid days 1-28, every 6 weeks, total 8 cycles, <sup>e)</sup>Oxaliplatin 85 mg/m<sup>2</sup> day 1+leucovorin 400 mg/m<sup>2</sup> day 1+5-FU 400 mg/m<sup>2</sup> iv push day 1+5-FU 2,400 mg/m<sup>2</sup> day 1, every 2 weeks, total 12 cycles. Oxaliplatin 130 mg/m<sup>2</sup> day 1+capecitabine 1,000 mg/m<sup>2</sup> P.O. bid days 1-14, every 3 weeks, total 8 cycles, <sup>f)</sup>Leucovorin 20 mg/m<sup>2</sup> iv push days 1-5+5-FU 425/m<sup>2</sup> iv push days 1-5, every 4 weeks, total 6 cycles. Capecitabine 1,250 mg/m<sup>2</sup> PO. bid days 1-14, every 3 weeks, total 8 cycles.